SCHEMBL3286567

SCHEMBL3286567

C#CCOc1ccc(C(=O)NC(C)CCC)cc1OC

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.66
PPARG P37231 1/20 0.66
NCOA3 Q9Y6Q9 1/20 0.66
TAS1R3 Q7RTX0 9/20 0.64
TAS1R1 Q7RTX1 9/20 0.64
CYP2B6 P20813 1/20 0.50
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC2 Q92769 1/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PDE10A Q9Y233 1/20 0.44
PDE4B Q07343 1/20 0.44
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3287333 0.91 MAPK1 (0.57) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3288790 0.88 CYP2B6 (0.56) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3288140 0.86 TAS1R3 (0.56) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3292158 0.86 MAPK1 (0.57) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3284931 0.85 TAS1R3 (0.55) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL13325337 0.85 CYP2B6 (0.53) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3285666 0.85 CYP2B6 (0.53) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3286728 0.85 CYP2B6 (0.53) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3292834 0.84 SMPD1 (0.51) RAB9APPARGNCOA3TAS1R3TAS1R1
SCHEMBL3286037 0.84 CYP2B6 (0.50) RAB9APPARGNCOA3TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714168-B2 N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
US-7714168-B2 N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
US-7714168-B2 N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-1940779-B1 AMIDE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL CO (JP) 2009-07-22 EP disclosed
US-20080319080-A1 Amide Compounds and Their Use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-12-25 US disclosed
US-20080319080-A1 Amide Compounds and Their Use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-12-25 US disclosed
US-20080319080-A1 Amide Compounds and Their Use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-12-25 US disclosed
EP-1940779-A2 AMIDE COMPOUNDS AND THEIR USE Sumitomo Chemical Company, Limited (JP) 2008-07-09 EP disclosed
WO-2007049729-A2 AMIDE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-03 WO disclosed
WO-2007049729-A2 AMIDE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319080-A1 Amide Compounds and Their Use NAT1, ACAT2, NAAA RAB9A 211/4885PPARG 102/4885NCOA3 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.